Lyons Wealth Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Lyons Wealth Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-19,000	Closed	-$61K	–	88
2015 Q4	$61K	Hold	19,000	–	–	0.08%	56
2015 Q3	$119K	Sell	19,000 -1,000	-5%	-$9.35K	0.15%	48
2015 Q2	$199K	Hold	20,000	–	–	0.23%	52
2015 Q1	$147K	Hold	20,000	–	–	0.16%	50
2014 Q4	$107K	Buy	+20,000	New	+$102K	0.11%	49

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lyons Wealth Management's NWBO Position: Q1 2016 in Review

Lyons Wealth Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2016, closing a stake of 19,000 shares — an estimated $61K sold.

Lyons Wealth Management first reported a position in NWBO in Q4 2014 and held it in 5 quarters. The position peaked at $199K in Q2 2015. 74 funds tracked by Wall St. Rank hold NWBO as of Q1 2016.

Lyons Wealth Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2016 after selling out during the quarter.
Lyons Wealth Management sold 19,000 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2016, an estimated $61K.
Lyons Wealth Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2014 and held it in 5 quarters.
Lyons Wealth Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $199K in Q2 2015.
74 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2016.

Based on Lyons Wealth Management's 13F filing for Q1 2016, filed 20 May 2016.